Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Sab Biotherapeutics Inc WT (SABSW)

Sab Biotherapeutics Inc WT (SABSW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results Globe Newswire - Wed Aug 10, 2022

Expects cash is sufficient to fund operations for the forward twelve months...

SABS : 2.80 (-2.10%)
SABSW : 0.0333 (-33.27%)
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down Globe Newswire - Tue Aug 9, 2022

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

SABS : 2.80 (-2.10%)
SABSW : 0.0333 (-33.27%)
SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer Globe Newswire - Mon Jun 6, 2022

SIOUX FALLS, S.D., June 06, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

SABS : 2.80 (-2.10%)
SABSW : 0.0333 (-33.27%)
SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit Globe Newswire - Tue May 31, 2022

In-person presentation titled ‘Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutics’ to take place on June 7 in Park City,...

SABS : 2.80 (-2.10%)
SABSW : 0.0333 (-33.27%)
SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results Globe Newswire - Thu May 12, 2022

Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel...

SABS : 2.80 (-2.10%)
SABSW : 0.0333 (-33.27%)
SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference Globe Newswire - Thu May 12, 2022

SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the H.C. Wainwright Global...

SABSW : 0.0333 (-33.27%)
SABS : 2.80 (-2.10%)
SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors Globe Newswire - Tue Apr 5, 2022

SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

SABS : 2.80 (-2.10%)
SABSW : 0.0333 (-33.27%)
SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results Globe Newswire - Tue Mar 29, 2022

SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised...

SABS : 2.80 (-2.10%)
SABSW : 0.0333 (-33.27%)
SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations Globe Newswire - Wed Mar 2, 2022

NIH is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design...

SABS : 2.80 (-2.10%)
SABSW : 0.0333 (-33.27%)
SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants Globe Newswire - Tue Mar 1, 2022

In the FDA-conducted study, SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2...

SABS : 2.80 (-2.10%)
SABSW : 0.0333 (-33.27%)

Barchart Exclusives

Up 128% YTD, Should You Still Invest in Nvidia Stock? Barchart - Sat Jul 27, 10:45AM CDT
For investors looking to capitalize on a leader in the AI revolution, Nvidia remains a compelling opportunity with a promising outlook. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot